Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Efficacy and safety of fingolimod and dimethyl fumarate for management of multiple sclerosis: A single center retrospective study.
Multiple Sclerosis
P6 - Poster Session 6 (12:00 PM-1:00 PM)
9-006
To observe the efficacy and safety of fingolimod and dimethyl fumarate (DMF) in patients with relapsing multiple sclerosis (RMS). 
Fingolimod was the very first oral disease modifying therapy (oDMT) approved by FDA in 2010 for treatment of RMS. It has changed the therapeutic paradigm of the disease. ODMT are now commonly used as a first line of treatment

Retrospective chart review of patient’s with multiple sclerosis (MS), treated with fingolimod and DMF was performed. Patients demographics, duration of disease, type of MS, side effects of medications, clinical and radiographic data were recorded. We performed a survival analysis using Kaplan-Meier methods and cox proportional hazards modeling and report hazard ratio of relapse and MRI lesions.

 
Our study population consisted of 141 patients: 111(79%) on DMT and 30(21%) on Fingolimod. Median(IQR) age was 50(42-56), 76% female, and 59% White. Median(IQR) disease duration was 12(8-19) years and time on oDMT was 2.8 (1.2-3.9) years. The percentage of patients who experienced side-effects was 40%; with flushing common in DMF(23% vs 0%, p<0.01) and bradycardia common in Fingolimod(10% vs 1%, p<0.01). Median(IQR) time to first relapse post-oDMT initiation was 1.2 (0.2-2.9) years with no statistically significant difference between the two groups.  Median (IQR) time to new/enhanced brain T2 MRI lesion post-oDMT initiation was shorter for DMF compared to Fingolimod: 0.9(0.2-1.5) vs 1.4(0.7-2.3), respectively(p<0.01).  

The interesting finding of our study is a shorter median (IQR) time to new or enhanced Brain MRI lesions in DMF group compared to Fingolimod group. The time to first relapse was not significantly different between groups. The limitation of our study is a small sample size and retrospective design. The complete data analysis of over 300 patients will be presented at Â鶹´«Ã½Ó³»­ 2020.

Authors/Disclosures
Anza B. Memon, MD, FÂ鶹´«Ã½Ó³»­ (Wayne State University, SOM, Detroit, MI)
PRESENTER 		Dr. Memon has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Inlightened. Dr. Memon has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Connected Research. Dr. Memon has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon Therapeutic . The institution of Dr. Memon has received research support from Genentech. The institution of Dr. Memon has received research support from TG Therapeutics.
Lara Fahmy, MSc Ms. Fahmy has nothing to disclose.
No disclosure on file
Mirela Cerghet, MD, PhD, FÂ鶹´«Ã½Ó³»­ (Henry Ford Hospital) Dr. Cerghet has nothing to disclose.